{"Symbol": "MRTX", "AssetType": "Common Stock", "Name": "Mirati Therapeutics, Inc", "Description": "Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. It is developing MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "9393 Towne Centre Drive, San Diego, CA, United States, 92121", "FullTimeEmployees": "111", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "6649035776", "EBITDA": "-148816000", "PERatio": "None", "PEGRatio": "0", "BookValue": "13.601", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-4.185", "RevenuePerShareTTM": "0.043", "ProfitMargin": "0", "OperatingMarginTTM": "-171.8439", "ReturnOnAssetsTTM": "-0.3283", "ReturnOnEquityTTM": "-0.5497", "RevenueTTM": "1781000", "GrossProfitTTM": "3335000", "DilutedEPSTTM": "-7.161", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.785", "AnalystTargetPrice": "137.57", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "3428.0224", "PriceToBookRatio": "10.8686", "EVToRevenue": "3329.4961", "EVToEBITDA": "0", "Beta": "1.7852", "52WeekHigh": "153.39", "52WeekLow": "66.01", "50DayMovingAverage": "130.2692", "200DayMovingAverage": "103.3568", "SharesOutstanding": "44540700", "SharesFloat": "28753690", "SharesShort": "4992606", "SharesShortPriorMonth": "5133912", "ShortRatio": "15.82", "ShortPercentOutstanding": "0.11", "ShortPercentFloat": "0.1253", "PercentInsiders": "9.319", "PercentInstitutions": "100.546", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:50", "LastSplitDate": "2013-07-03"}